ArticleFrontiers in microbiology2016
Activity of Scorpion Venom-Derived Antifungal Peptides against Planktonic Cells of
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 63 citations in OpenAlex.
- Scorpion Peptides in Antiviral Drug Discovery: An In-depth Review.Probiotics and antimicrobial proteins · 2026Review
- Enhancement of the activity of scorpion short-chain antimicrobial peptides by addition of basic residues at the C-terminus.Journal of pesticide science · 2026Article
- Scorpion venom as a source of new antimicrobial agents.Frontiers in microbiology · 2026Review
- Properties and Pharmacology of Scorpion Toxins and Their Biotechnological Potential in Agriculture and Medicine.Toxins · 2025Review
- Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Natural Source-Derived Compounds with Antifungal Activity Against Medically Relevant Fungi.Infection and drug resistance · 2025Review
- Characterization ofFrontiers in pharmacology · 2025Article
- Antimicrobial Potential of Scorpion-Venom-Derived Peptides.Molecules (Basel, Switzerland) · 2024Review
- Harnessing the potency of scorpion venom-derived proteins: applications in cancer therapy.Bioresources and bioprocessing · 2024Review
- A Critical Review of Short Antimicrobial Peptides from Scorpion Venoms, Their Physicochemical Attributes, and Potential for the Development of New Drugs.The Journal of membrane biology · 2024Review
- Synergic Effect of the Antimicrobial Peptide ToAP2 and Fluconazole onInternational journal of molecular sciences · 2024Article
- Scorpion Venom Antimicrobial Peptide Derivative BmKn2-T5 Inhibits Enterovirus 71 in the Early Stages of the Viral Life CycleBiomolecules · 2024Article
- Exploring the potential of Brazilian Amazonian scorpion venoms: A comprehensive review of research from 2001 to 2021.Toxicon: X · 2024Review
- The effects of antimicrobial peptides buCaTHL4B and Im-4 on infectious root canal biofilms.Frontiers in bioengineering and biotechnology · 2024Article
- The Identification of a Novel Spider Toxin Peptide, Lycotoxin-Pa2a, with Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2023Article
- Mechanistic Insight into the Early Stages of Toroidal Pore Formation by the Antimicrobial Peptide Smp24.Pharmaceutics · 2023Article
- Identification of an Antimicrobial Peptide from the Venom of the Trinidad Thick-Tailed ScorpionAntibiotics (Basel, Switzerland) · 2023Article
- Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom.Scientific reports · 2023Article
- Innovative Pre-Clinical Data Using Peptides to Intervene in the Evolution of Pulmonary Fibrosis.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of fungal infections has been increasing in the last decades, while the number of available antifungal classes remains the same. The natural and acquired resistance of some fungal species to available therapies, associated with the high toxicity of these drugs on the present scenario and makes an imperative of the search for new, more efficient and less toxic therapeutic choices. Antimicrobial peptides (AMPs) are a potential class of antimicrobial drugs consisting of evolutionarily conserved multifunctional molecules with both microbicidal and immunomodulatory properties being part of the innate immune response of diverse organisms. In this study, we evaluated 11 scorpion-venom derived non-disulfide-bridged peptides against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.